Precision Business Insights
Portfolio

 

Research Reports

Rheumatic Disorders Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

Global Rheumatic Disorders Treatment Market: By Disease (Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Gout, and Others), By Treatment (Narcotic Analgesics, NSAIDS, Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Response Modifiers (Monoclonal Antibodies (mAb), TNF Inhibitors, Interleukin (IL) Inhibitors, JAK inhibitors), and Others), and Geography

 

 

Global Rheumatic Disorders Treatment Market:

The global rheumatic disorders treatment market estimated to be valued US$ XX Mn in 2018 and projected to grow at significant CAGR over 2019-2025 owing to rise in the incidence of number of indications within the rheumatic disorders and increase in prevalence of geriatric population are the major factors that are driving the growth of the market. The launch of new products (block buster products) coupled with the expiration of patent for the TNF inhibitors will drive the market over the forecast years.

 

IL Inhibitors and JAK Inhibitors Treatment Segment is expected to grow at Highest CAGR over the Forecast Years

Based on Treatment, IL inhibitors and JAK inhibitors treatment segment is expected to grow at highest CAGR over the forecast years owing to soon expiry of TNF inhibitors and growing geriatric population enhances the growth of the market for rheumatic disorders treatment market. Market players in rheumatic disorders are having at least one marketed or pipeline rheumatic disorders products.

 

North America Accounts the Larger Market Revenue Share in Global Rheumatic Disorders Treatment Market

North America accounted for larger revenue share in global rheumatic disorders treatment market with significant CAGR owing to increase in prevalence of rheumatic disorders and OA is the most common disorder that affects almost 28 million adults in the United States alone. Moreover, presence of large number of market players and launch of new products coupled with the approval for new products and high investments in research and developments for the development of new product are the major factors enhancing the growth of the market.

 

Competition Assessment

Key player’s profiles in the global rheumatic disorders treatment market include:

  • AbbVie
  • Amgen
  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • ChemoCentryx
  • Corbus Pharmaceuticals
  • Eli Lilly
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Roche
  • Selecta Biosciences
  • UCB

 

Global rheumatic disorders treatment market is surging owing to approvals and launch of new products in the market to enhance the growth of the company. For instance, in June 2018, Eli Lilly and Company announced that the USFDA has approved the 2-mg dose of OLUMIANT® (baricitinib), a once-daily oral medication for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitor therapies.

 

Key Findings of the Report:

 

  • Global rheumatic disorders treatment market expanding at significant CAGR over 2019 to 2025 owing to approval and launch of new products into the market.
  • Based on Treatment, Biologic response modifiers segment of rheumatic disorders treatment accounted for larger market revenue share in 2018 and projected gain market revenue share over the forecast period
  • Players focusing on launch of newer products and collaboration strategies to retain market position in global rheumatic disorders treatment market

 

Global Rheumatic Disorders Treatment Market Report Description:

Global rheumatic disorders treatment market report gives comprehensive outlook on rheumatic disorders treatment across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report on global rheumatic disorders treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of product and services, application, sector, and region. This report studies global rheumatic disorders treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global rheumatic disorders treatment market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global rheumatic disorders treatment market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global rheumatic disorders treatment market report include suppliers, manufacturers, marketers, policy makers, and service providers engaged in global rheumatic disorders treatment products

 

Detailed Segmentation

 

By Disease  

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Osteoporosis
  • Systemic Lupus Erythematosus
  • Psoriatic Arthritis
  • Gout
  • Others

By Treatment

  • Narcotic Analgesics
  • NSAIDS
  • Corticosteroids
  • Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  • Biologic Response Modifiers
    • Monoclonal Antibodies (mAb)
    • TNF Inhibitors
    • Interleukin (IL) Inhibitors (IL)
    • JAK inhibitors
  • Others

Geography

 

North America

  • US
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

 

Key Features of the Report:

 

  • The report provides granular level information about the market size, regional market share, historic market (2014-2018) and forecast (2019-2025)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  1. Executive Summary
  2. Global Rheumatic Disorders Treatment Market Introduction

2.1. Global Rheumatic Disorders Treatment Market – Taxonomy

2.2. Global Rheumatic Disorders Treatment Market –Definitions

2.2.1. By Disease

2.2.2. By Treatment

2.2.3. By Distribution Channel

  1. Global Rheumatic Disorders Treatment Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Rheumatic Disorders Treatment Market Dynamics – Factors Impact Analysis

  1. Global Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

  1. Global Rheumatic Disorders Treatment Market Forecast, By Disease, 2014 – 2018 and Forecast, 2019 – 2025

5.1. Rheumatoid Arthritis

5.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Osteoarthritis

5.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Osteoporosis

5.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

5.4. Systemic Lupus Erythematosus

5.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

5.5. Psoriatic Arthritis

5.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

5.6. Gout

5.6.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.6.3. Market Opportunity Analysis

5.7. Others

5.7.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.7.3. Market Opportunity Analysis

  1. Global Rheumatic Disorders Treatment Market Forecast, By Treatment, 2014 – 2018 and Forecast, 2019 – 2025

6.1. Narcotic Analgesics

6.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. NSAIDS

6.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Corticosteroids

6.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

6.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

6.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.4.3. Market Opportunity Analysis

6.5. Biologic Response Modifiers

6.5.1. Monoclonal Antibodies

6.5.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.1.3. Market Opportunity Analysis

6.5.2. TNF Inhibitors

6.5.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.2.3. Market Opportunity Analysis

6.5.3. Interleukin Inhibitors

6.5.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.3.3. Market Opportunity Analysis

6.5.4. JAK Inhibitors

6.5.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.4.3. Market Opportunity Analysis

6.6. Others

6.6.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.6.3. Market Opportunity Analysis

  1. Global Rheumatic Disorders Treatment Market Forecast, By Distribution Channel, 2014 – 2018 and Forecast, 2019 – 2025

7.1. Hospital Pharmacies

7.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

7.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Online Pharmacies

7.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

  1. Global Rheumatic Disorders Treatment Market Forecast, By Region, 2014 – 2018 and Forecast, 2019 – 2025

8.1. North America

8.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Asia Pacific

8.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

8.5. The Middle East & Africa

8.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

8.6. Global Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Region, 2019 – 2025

  1. North America Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

9.1. Disease Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1. Rheumatoid Arthritis

9.1.2. Osteoarthritis

9.1.3. Osteoporosis

9.1.4. Systemic Lupus Erythematosus

9.1.5. Psoriatic Arthritis

9.1.6. Gout

9.1.7. Others

9.2. Treatment Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.2.1. Narcotic Analgesics

9.2.2. NSAIDS

9.2.3. Corticosteroids

9.2.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

9.2.5. Biologic Response Modifiers

9.2.5.1. Monoclonal Antibodies (mAb)

9.2.5.2. TNF Inhibitors

9.2.5.3. Interleukin (IL) Inhibitors (IL)

9.2.5.4. JAK inhibitors

9.2.6. Others     

9.3. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Pharmacies

9.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2019 – 2025

9.6. North America Rheumatic Disorders Treatment Market Dynamics – Trends

  1. Europe Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

10.1. Disease Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Rheumatoid Arthritis

10.1.2. Osteoarthritis

10.1.3. Osteoporosis

10.1.4. Systemic Lupus Erythematosus

10.1.5. Psoriatic Arthritis

10.1.6. Gout

10.1.7. Others

10.2. Treatment Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.2.1. Narcotic Analgesics

10.2.2. NSAIDS

10.2.3. Corticosteroids

10.2.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

10.2.5. Biologic Response Modifiers

10.2.5.1. Monoclonal Antibodies (mAb)

10.2.5.2. TNF Inhibitors

10.2.5.3. Interleukin (IL) Inhibitors (IL)

10.2.5.4. JAK inhibitors

10.2.6. Others     

10.3. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Online Pharmacies

10.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. U.K.

10.4.2. Germany

10.4.3. France

10.4.4. Italy

10.4.5. Spain

10.4.6. Russia

10.4.7. Rest of Europe

10.5. Europe Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2019 – 2025

10.6. Europe Rheumatic Disorders Treatment Market Dynamics – Trends

  1. Asia Pacific Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

11.1. Disease Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Rheumatoid Arthritis

11.1.2. Osteoarthritis

11.1.3. Osteoporosis

11.1.4. Systemic Lupus Erythematosus

11.1.5. Psoriatic Arthritis

11.1.6. Gout

11.1.7. Others

11.2. Treatment Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.2.1. Narcotic Analgesics

11.2.2. NSAIDS

11.2.3. Corticosteroids

11.2.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

11.2.5. Biologic Response Modifiers

11.2.5.1. Monoclonal Antibodies (mAb)

11.2.5.2. TNF Inhibitors

11.2.5.3. Interleukin (IL) Inhibitors (IL)

11.2.5.4. JAK inhibitors

11.2.6. Others     

11.3. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.3.1. Hospital Pharmacies

11.3.2. Retail Pharmacies

11.3.3. Online Pharmacies

11.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. ASEAN Counties

11.4.5. Philippines

11.4.6. Rest of Asia Pacific

11.5. Asia Pacific Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2019 – 2025

11.6. Asia Pacific Rheumatic Disorders Treatment Market Dynamics – Trends

  1. Latin America Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

12.1. Disease Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. Rheumatoid Arthritis

12.1.2. Osteoarthritis

12.1.3. Osteoporosis

12.1.4. Systemic Lupus Erythematosus

12.1.5. Psoriatic Arthritis

12.1.6. Gout

12.1.7. Others

12.2. Treatment Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.2.1. Narcotic Analgesics

12.2.2. NSAIDS

12.2.3. Corticosteroids

12.2.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

12.2.5. Biologic Response Modifiers

12.2.5.1. Monoclonal Antibodies (mAb)

12.2.5.2. TNF Inhibitors

12.2.5.3. Interleukin (IL) Inhibitors (IL)

12.2.5.4. JAK inhibitors

12.2.6. Others     

12.3. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.3.1. Hospital Pharmacies

12.3.2. Retail Pharmacies

12.3.3. Online Pharmacies

12.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Mexico

12.4.2. Brazil

12.4.3. Argentina

12.4.4. Chile

12.4.5. Rest of Latin America

12.5. Latin America Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2019 – 2025

12.6. Latin America Rheumatic Disorders Treatment Market Dynamics – Trends

  1. Middle East and Africa Rheumatic Disorders Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

13.1. Disease Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. Rheumatoid Arthritis

13.1.2. Osteoarthritis

13.1.3. Osteoporosis

13.1.4. Systemic Lupus Erythematosus

13.1.5. Psoriatic Arthritis

13.1.6. Gout

13.1.7. Others

13.2. Treatment Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.2.1. Narcotic Analgesics

13.2.2. NSAIDS

13.2.3. Corticosteroids

13.2.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

13.2.5. Biologic Response Modifiers

13.2.5.1. Monoclonal Antibodies (mAb)

13.2.5.2. TNF Inhibitors

13.2.5.3. Interleukin (IL) Inhibitors (IL)

13.2.5.4. JAK inhibitors

13.2.6. Others     

13.3. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.3.1. Hospital Pharmacies

13.3.2. Retail Pharmacies

13.3.3. Online Pharmacies

13.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Saudi Arabia

13.4.4. Turkey

13.4.5. Rest of MEA

13.5. Middle East and Africa Rheumatic Disorders Treatment Market – Opportunity Analysis Index, By Disease, By Treatment, BY Distribution Channel, and Country, 2019 – 2025

13.6. Middle East and Africa Rheumatic Disorders Treatment Market Dynamics – Trends

  1. Competition Landscape

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Key Developments, Strategies, and SWOT Analysis)

14.2.1. AbbVie

14.2.2. Amgen

14.2.3. Astellas

14.2.4. AstraZeneca

14.2.5. Bristol-Myers Squibb

14.2.6. ChemoCentryx

14.2.7. Corbus Pharmaceuticals

14.2.8. Eli Lilly

14.2.9. Gilead Sciences

14.2.10. GlaxoSmithKline

14.2.11. Johnson & Johnson

14.2.12. Novartis

14.2.13. Pfizer

14.2.14. Roche

14.2.15. Selecta Biosciences

14.2.16. UCB

  1. Research Methodology
  2. Key Assumptions and Acronyms

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials

Contact SalesTOLL FREE: +1-866-598-1553